The Effect of *Tsukamurella inchonensis* Bacterin on the Immune Response Against Influenza and Newcastle Disease Vaccines in Broiler Chickens

Forough Talazadeh¹, Mansour Mayahi², Katayoon Nofouzi³, Ebrahim Golzari⁴, Rahil Chegini⁴

¹Assistant Professor, Department of Clinical Sciences, Faculty of Veterinary Medicine, Shahid Chamran University of Ahvaz, Ahvaz, Iran
²Professor, Department of Clinical Sciences, Faculty of Veterinary Medicine, Shahid Chamran University of Ahvaz, Ahvaz, Iran
³Associate Professor, Department of Pathobiology, Faculty of Veterinary Medicine, University of Tabriz, Tabriz, Iran
⁴Graduate from Faculty of Veterinary Medicine, Shahid Chamran University of Ahvaz, Ahvaz, Iran

Abstract

**Background:** In poultry production, improving immunity is very important in preventing infectious diseases. One solution to improve the immunity of animals and to decrease their susceptibility to infectious diseases is administration of immunostimulants. Surveys have indicated that some bacteria such as *Mycobacterium vaccae* can work as immunomodulators, promote Th1-mediated mechanisms, and switch off pre-existing Th2 preponderance.¹

**Objectives:** The aim of this study was to examine the effect of *Tsukamurella inchonensis* bacterin on the immune response against influenza and Newcastle disease (ND) vaccines in broiler chickens.

**Materials and Methods:** A total of 170 one-day-old broiler chicks were purchased and divided randomly into 5 equal groups. Chickens of group A received $10^6$ bacterin subcutaneously 2 days before vaccination against ND and avian influenza (AI). Chickens of group B received $10^6$ bacterin subcutaneously 6 days after the first injection of bacterin. Chickens of group C received $10^6$ bacterin subcutaneously 6 days after the second injection of bacterin. Chickens of group D were vaccinated against ND and AI but did not receive bacterin. Chickens of group E were not vaccinated against ND and AI and did not receive bacterin. All groups except group E were vaccinated with live Newcastle vaccine and AI-ND killed vaccine (subtype H9N2). Blood samples were collected and antibody titer against ND vaccine and AI vaccine was determined by hemagglutination inhibition (HI) test.

**Results:** The results of present study showed that receiving *T. inchonensis* bacterin for 3 times significantly increased the specific antibody response to AI subtype H9N2 vaccine. Moreover, the specific antibody response to Newcastle vaccine was significantly increased at days 21 and 28 after vaccination.

**Conclusion:** Receiving *T. inchonensis* bacterin can enhance immune response against ND virus and AI virus.

**Keywords:** Avian influenza virus (AIV), *Tsukamurella inchonensis* bacterin, Immune response, ND virus, Broiler chickens

Background

The successful poultry production is based on feeding, breeding, marketing, management, and the well-developed immune status of the birds. Immunity means the power of resistance against the pathogenic microorganisms. Such power of defense has two main sources; natural and induced. Schat and Myers² stated that the natural immunity in the avian is transmitted through egg yolk, which directly releases maternal antibodies into the intestine and causes protection against infections in the young chicks. Efforts have been made to compensate the natural immune status of the broilers.

**Influenza viruses**

Influenza viruses belong to the family of Orthomyxoviridae. They have negative-strand RNA, are segmented, and have three types, A, B, and C.³ Avian influenza viruses (AIVs) belong to type A, but all three types of influenza viruses...
are found in humans. H9N2 virus shares similar receptor binding epitopes with human influenza viruses, so H9N2 virus infects a wide range of hosts, including humans. H9N2 AIV infection has also a latent feature and can easily be ignored, so there is a rising chance to infect humans.¹

Newcastle Disease

Newcastle Disease (ND) is a deadly viral disease that can infect poultry. It was first isolated in England in 1926. This viral disease is reckoned as one of the great economic dangers to birds because it causes high mortality and morbidity that, depending on the type of ND virus, varies between 90%-100%.³ It is an acute, contagious infection of domestic birds, free living, and pet. Avian paramyxovirus type 1 causes ND. Firstly, ND was reported in Southeast Asia in 1926.³ Since then, it has become one of the very serious economic dangers to birds all over the world.⁴ ND virus belongs to the order Mononegavirales, family Paramyxoviridae, subfamily Paramyxovirinae, genus Rubulavirus.⁵,⁶,⁷ The virus is negative-sense, enveloped, single-stranded RNA genome.⁸ The use of safe and good vaccines is very important in controlling the ND.

Tsukamurella ssp.

Tsukamurella ssp., which belong to the family Nocardiaceae, are weakly or variably acid-fast, non-spore-forming, gram-positive, nonmotile, obligate, rod-shaped, and aerobic actinomycetes. They are environmental saprophytes; soil, sludge, and arthropods are their natural habitats. Tsukamurella ssp., pathogenic to humans, include T. paurometabolum,¹⁰,¹¹ T. inchonensis,¹²,¹³ T. pulmonis,¹⁴ and T. tyrosinosolvens.¹⁵

Description of Tsukamurella inchonensis

Tsukamurella inchonensis does not have capsules. It is acid-alcohol-fast bacterium. Colonies are brownish orange, and rough on Loewenstein Jensen medium. At 24, 31, 37, and 45°C, growth of T. inchonensis occurs. T. inchonensis has meso-diaminopimelic acid in addition to diamino acid, arabinose, and galactose as determined with whole-cell hydrolysates; the cell wall chemotype is chemotype IV (12).

Objectives

The aim of this study was to examine the effect of T. inchonensis bacterin on the immune response against influenza and ND vaccines in broiler chickens.

Materials and Methods

Chickens

A total of 170 one-day-old broiler chicks were purchased and 20 chicks were bled for determination of maternal antibody and remaining chicks were divided randomly into 5 equal groups and each group was divided into 3 equal subgroups.

Vaccinia

Hitchner B1 vaccine Cevac® and AI- ND killed vaccine (subtype H9N2) were supplied.

Tsukamurella inchonensis

Tsukamurella inchonensis was supplied from BioEos Ltd (Kent, UK).

Experimental Design

Chickens of group A received 10⁶ bacterin subcutaneously 2 days before vaccination against ND and avian influenza (AI). Chickens of group B received 10⁶ bacterin subcutaneously 6 days after the first injection of bacterin. Chickens of group C received 10⁶ bacterin subcutaneously 6 days after the second injection of bacterin. Chickens of group D were vaccinated against ND and AI, but did not receive bacterin. Chickens of group E were not vaccinated against ND and AI, and did not receive bacterin. All groups except group E were vaccinated with live Newcastle vaccine (B1 strain) intraocularly and AI-ND killed vaccine (subtype H9N2) subcutaneously, at neck back at 9 days old.

Blood Collection and Serological Tests

Blood samples were collected before vaccination as well as on days 14, 21, and 28 post-immunization. Ten chickens of each group were bled randomly and antibody titers against ND and Influenza virus vaccines was determined by Hemagglutination inhibition (HI) test. Brachial vein was used and blood samples were drained from, and sera were frozen at -20°C. HI test was performed to detect antibodies against AIV and NDV in serum samples according to Alexander et al.¹⁶

Microplate hemagglutination inhibition test

Beta procedure of micro-plate HI test was performed in U-bottomed 96-well μL plates with 1% chicken RBC to determine the antibody level of the sera samples. Four HA unit AIV and 4 HA unit ND virus were used in this test.

Statistical Analysis

SPSS version 18.0 was used to analyze the titers obtained by HI test. After vaccination, the significant differences in HI titres of chickens of each group were determined by one-way analysis of variance (ANOVA) LSD test. Means were compared at a significance level of 5%.

Results

As shown in Table 1, the results indicated that 14 days after vaccination, there was a significant difference between all groups and group E (unvaccinated control). But 14 days after vaccination, there was not any significant difference between those groups that received injection of bacterin and group D (vaccinated control). Twenty-one days after vaccination, there was a significant difference between all groups and group E (unvaccinated control), and between all groups and group D (vaccinated control), but there was not any significant difference between those groups that received injection of bacterin. Twenty-eight days after vaccination, there was a significant difference
Table 1. The Effect of Tsukamurella inchonensis on HI Antibody Titer Against ND Vaccine in Broiler Chicks

<table>
<thead>
<tr>
<th>Groups</th>
<th>Days Post-vaccination</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0</td>
</tr>
<tr>
<td>A</td>
<td>6.75 ± 0.88</td>
</tr>
<tr>
<td>B</td>
<td>6.75 ± 0.88</td>
</tr>
<tr>
<td>C</td>
<td>6.75 ± 0.88</td>
</tr>
<tr>
<td>D (vaccinated)</td>
<td>6.75 ± 0.88</td>
</tr>
<tr>
<td>E (unvaccinated)</td>
<td>6.75 ± 0.88</td>
</tr>
</tbody>
</table>

Abbreviations: ND, Newcastle disease; HI, hemagglutination inhibition. The groups with different superscripts are significantly different in each column (P<.05). *Mean ± standard deviation.

Table 2. The Effect of Tsukamurella inchonensis on HI Antibody Titer Against AI Disease Vaccine

<table>
<thead>
<tr>
<th>Groups</th>
<th>Days Post-vaccination</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0</td>
</tr>
<tr>
<td>A</td>
<td>6 ± 0.9</td>
</tr>
<tr>
<td>B</td>
<td>6 ± 0.9</td>
</tr>
<tr>
<td>C</td>
<td>6 ± 0.9</td>
</tr>
<tr>
<td>D (vaccinated)</td>
<td>6 ± 0.9</td>
</tr>
<tr>
<td>E (unvaccinated)</td>
<td>6 ± 0.9</td>
</tr>
</tbody>
</table>

Abbreviations: AI, avian influenza; HI, hemagglutination inhibition. The groups with different superscripts are significantly different in each column (P<.05). *Mean ± standard deviation.

between all groups and group E (unvaccinated control), and between all groups and group D (vaccinated control), but there was not any significant difference between those groups that received injection of bacterin. As seen in Table 2, the results indicated that 14 days after vaccination, there was a significant difference between all groups and group E (unvaccinated control). Fourteen days after vaccination, there was also a significant difference between groups A and C, and between groups D and C, and group C (receiving 3 injections of bacterin) had the highest antibody titer compared to group A (receiving one injection of bacterin) and group D (vaccinated control). Twenty-one days after vaccination, there was a significant difference between all groups and group E (unvaccinated control). Additionally, 21 days after vaccination, there was a significant difference between groups A and C, and between groups D and C, and group C (receiving 3 times of bacterin injection) had the highest antibody titer compared to group B (receiving 2 injections of bacterin) and group D (vaccinated control). Twenty-eight days after vaccination, there was a significant difference between all groups and group E (unvaccinated control). And 28 days after vaccination, there was a significant difference between groups D and C, and group C (receiving 3 times of bacterin injection) had higher antibody titer than group D (vaccinated control).

**Discussion**

Studies have indicated that some bacteria such as Mycobacterium vaccae can work as immunomodulators promote Th1-mediated mechanisms, and switch off pre-existing Th2 preponderance. Recently, some other aerobic Actinomycetales species closely related to mycobacteria, including Rhodococcus coprophilus (Rc), Gordonia bronchialis (Gb), and Tsukamurella inchonensis (Ti), which have immunomodulatory or adjuvant activities when injected as suspension of killed bacilli, have been identified. Immunotherapy can change a person’s immune response to reduce infection either by reducing the severity of the condition or protecting against it. Then, sensitivity to an allergen that causes allergic signs, such as asthma or allergic rhinitis in allergen immunotherapy, is reduced. For modification of the response to venoms, such as those of wasps or bees, for people with acute reactions, subsequent to prior exposure, venom immunotherapy is used. Immunotherapy has been tested for parasitic diseases, chronic bacterial diseases, and chronic viral diseases. The host immune response affects the damage caused by the infection in tuberculosis. A mixed lymphocyte response including both type 1 and type 2 responses are more likely to be associated with death of local tissues than a type 1 lymphocyte response in experiments that are performed in animals. In tuberculosis, a type 1 response has an important role in immunity against infection that is characterized by production of gamma interferon. A fast-growing mycobacterium species that is found in the environment is M. vaccae. As immunotherapy for tuberculosis, this bacterium has been used as a whole cell killed vaccine. It has been proposed that immunotherapy allows immune identification of antigens common to all mycobacteria or that immunotherapy shifts T-lymphocyte responses to a type 1 pattern. Some indirect experimental evidence indicates that the pattern occurs in humans. Recently, experimental studies have shown that immunotherapy can change the exposure to allergens in the immune system and reduce the severity of allergic reactions. Studies have indicated that some bacteria such as Mycobacterium vaccae can work as immunomodulators promote Th1-mediated mechanisms, and switch off pre-existing Th2 preponderance. Recently, some other aerobic Actinomycetales species closely related to mycobacteria, including Rhodococcus coprophilus (Rc), Gordonia bronchialis (Gb), and Tsukamurella inchonensis (Ti), which have immunomodulatory or adjuvant activities when injected as suspension of killed bacilli, have been identified. Immunotherapy can change a person’s immune response to reduce infection either by reducing the severity of the condition or protecting against it. Then, sensitivity to an allergen that causes allergic signs, such as asthma or allergic rhinitis in allergen immunotherapy, is reduced. For modification of the response to venoms, such as those of wasps or bees, for people with acute reactions, subsequent to prior exposure, venom immunotherapy is used. Immunotherapy has been tested for parasitic diseases, chronic bacterial diseases, and chronic viral diseases. The host immune response affects the damage caused by the infection in tuberculosis. A mixed lymphocyte response including both type 1 and type 2 responses are more likely to be associated with death of local tissues than a type 1 lymphocyte response in experiments that are performed in animals. In tuberculosis, a type 1 response has an important role in immunity against infection that is characterized by production of gamma interferon. A fast-growing mycobacterium species that is found in the environment is M. vaccae. As immunotherapy for tuberculosis, this bacterium has been used as a whole cell killed vaccine. It has been proposed that immunotherapy allows immune identification of antigens common to all mycobacteria or that immunotherapy shifts T-lymphocyte responses to a type 1 pattern. Some indirect experimental evidence indicates that the pattern occurs in humans. Recently, experimental
evidence has demonstrated that by vaccination with M. 
vaccine, through induction of regulatory T cells, allergic 
responses can be reduced. Immunotherapy may cause a 
more rapid recovery from disease, because it allows the 
host to ruin infectious agents.

In conclusion, the results of the present study indicated 
that 21 and 28 days after vaccination, receiving bacterin 
could improve antibody titer against ND vaccine com- 
pared to vaccinated control group. The present study also 
indicated that 3 times of bacterin injection could improve 
antibody titer against AI disease vaccine.

Authors’ Contribution
Study concept and design: FT, MM, KN, EG, and RC; Analysis 
and interpretation of data: FT and MM; Drafting of the manuscript: 
FT; Critical revision of the manuscript for important intellectual 
content: FT and MM; Statistical analysis: FT.

Conflict of Interest Disclosures
None.

Ethical Approval
Ethical issues have been completely observed by the authors.

Funding/Support
This article was supported by Shahid Chamran University of Ahvaz, 
Ahvaz, Iran.

Acknowledgments
The authors are grateful to Shahid Chamran University of Ahvaz, 
Ahvaz, Iran, and John L Stanford “BioEos Ltd, Mill House, Claygate, 
Marden, Near Tonbridge, Kent, TN12 9PE, UK” for supporting this 
study.

References
     airway eosinophilia by killed Mycobacterium vaccae-induced 
     629.
2.  Schat KA, Myres TJ. Avian intestinal immunity. Crit Rev Poul 
     t Biol. 1991;3:19-34.
     DM, Howley PM, eds. Fields Virology. 5th ed. Lippincott, 
5.  Alexander DJ. Newcastle disease and other paramyxoviridae 
     infections. In: Calnek BW, Barnes HJ, Beard CW, McDougall 
     LR, Sait YM, eds. Diseases of Poultry. 10th ed. Ames, USA: 
     Iowa State University press; 1997:541-569.
     costs. Veterinary Record. 2000;146:603-605.
7.  Alexander DJ. Newcastle disease virus and other paramyxoviridae 
     JE, Reed WM, eds. A laboratory Manual for the isolation and 
     identification of Avian Pathogens. 4th ed. Kennett Square, PA: 
8.  Lamb RA, Kolakowski D. Paramyxoviridae: the viruses and 
     their replication. In: Fields BN, Knipe DM, Howley PM, eds 
9.  De Leeuw O, Peeters B. Complete nucleotide sequence of 
     Newcastle disease virus: evidence for the existence of a new 
     genus within the subfamily Paramyxovirinae. J Gen Virol. 
     infections. Review of the literature apropos of a case. Pathol. 
11. Granel F, Lozniewski A, Barbaud A. Cutaneous infection 
12. Yassin AF, Rainey FA, Brezziakina H, Burghardt J, Lee HJ, Schaal 
     614.
     Tsukamurella ichnovenis bacteremia in a patient who 
     1268.
     for haemagglutination inhibition test for antibodies to avian 
     infectious bronchitis virus. Veterinary Record. 1983;113:64.
     the prevention of myointimal hyperplasia after experimental 
     balloon injury of the rat carotid artery. Angiology 2010;61(5): 
18. Marro A, Pirles M, Schiiffrino L. Successful immunotherapy of 
     canine flea allergy with injected Actinomycetas preparation. 
     1881–1887.
     immunotherapy for asthma. Cochrane Database Syst Rev. 
21. Bouquet J, Lockey R, Malling HJ. Allergen immunotherapy: 
     therapeutic vaccines for allergic diseases. J Allergy Clin 
23. Convit J1, Castellanos PL, Ulrich M, et al. Immunotherapy of 
     localized, intermediate, and diffuse forms of American 
     genital herpes with recombinant herpes simplex virus type 
     2 glycoproteins D and B: results of a placebo-controlled 
25. Kahn JO, Cheng DW, Mayer K, Murray H, Lagakos S. 
     Evaluation of HIV-1 immunogen, an immunologic modifier, 
     administered to patients infected with HIV having 300 to 549 
     x 10(6)/L CD4 cell counts: A randomized controlled trial. 
26. Rook GA, Stanford JL.The Koch phenomenon and the 
     Current Topics in Microbiology and Immunology (vol 215). 
     Berlin: Springer-Verlag; 1997:226-239.
27. Grange JM. Pathogenesis of mycobacterial disease. In: 
     Gangadaram PRJ, Jenkins PA, eds. Mycobacteria (vol 1). 
28. Barnes PF, Wizel B. Type 1 cytokines and the pathogenesis of 
     1774.
     in immunophrophylaxis and immunotherapy of leprosy and 
30. Stanford JL, Stanford CA. Immunotherapy of tuberculosis with 